Lenvatinib combined with programmed cell death protein-1 (PD-1) inhibitors has resulted in good survival outcomes in the treatment of unresectable hepatocellular carcinoma (HCC). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.